Browse the evidence

Recent drug candidates show a convincing reduction of sleep disordered breathing in both short and intermediate term.

New drug candidates may offer effective treatment options for OSA patients.

GLP-1RAs may have little or no effect on breast cancer risk.

Practitioners should consider that GLP-1RAs may not significantly increase breast cancer risk based on current evidence.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.

Practitioners should be aware of the limitations of current oral obesity treatments.

A dual/poly-GPCR agonism strategy has emerged as an alternative approach to the traditional mono-GPCR concept.

Practitioners may consider exploring dual/poly-GPCR strategies in obesity treatment.

The mechanism-based therapeutic potential and limitations of oral poly-GPCR agonism strategy to augment intestinal GLP-1 for weight loss are projected.

Practitioners should evaluate the potential of oral poly-GPCR agonism in enhancing GLP-1 for weight loss.

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

Chronic co-administration of OXT and GLP-1 decreases body weight without changing food intake.

Combining OXT with GLP-1 may be an effective strategy for reducing body weight in obese populations.

Single injection of OXT/GLP-1 additively decreases food intake.

Using OXT in conjunction with GLP-1 may enhance appetite suppression effects.

If clinicians elect to use compounded incretin‐based therapy, they must consider the potential harms and benefits for each patient.

Clinicians should evaluate individual patient needs and educate them on therapy administration.

Obesity is associated with comorbidities such as metabolic and cardiovascular diseases, orthopaedic and psychiatric conditions, and cancer.

Healthcare providers should be aware of the serious health risks associated with obesity.

Diet and exercise are not effective as sole management of severe obesity.

Clinicians should consider additional interventions beyond diet and exercise for severe obesity.

Allodynia was observed in 4 patients associated with dose escalation of semaglutide.

Clinicians should be aware of the potential for allodynia in patients taking semaglutide.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Retatrutide raises cardiovascular safety concerns due to dose-dependent increases in heart rate and incidents of mild to moderate cardiac arrhythmias.

Clinicians should monitor cardiovascular health in patients using retatrutide.

Redemption was higher for females, Asian participants, and those reporting Spanish as their preferred language compared to their counterparts.

Demographic factors such as gender, ethnicity, and language preference may influence redemption rates in produce prescription programs.

BI 1820237 treatment was associated with transient nausea and vomiting at higher doses.

Practitioners should monitor for gastrointestinal side effects when prescribing BI 1820237.

Drug-related adverse events (AEs) were reported by 39.0% of participants in parts 1 + 2 and 30.6% in part 3.

Practitioners should be aware of the incidence of AEs when considering BI 1820237 for treatment.

Newer antiretroviral agents have been consistently associated with excessive weight gain.

Clinicians should consider the weight gain potential of newer ART agents when prescribing.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.

The review focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of anti-obesity drug discovery.

Practitioners should consider the role of GLP-1 RAs in developing new anti-obesity therapies.